Interchangeability: FDA Sets ‘Stringent’ Standard On Design Differences
Executive Summary
Sponsors must assess any differences in a biosimilar’s container closure system or delivery device relative to the US reference product and may need to conduct comparative use human factor studies to ensure there is no increased risk of use-related error with the biosimilar.
You may also be interested in...
Biosimilar Interchangeability Switching Studies May Use Foreign Comparators, US FDA Says
But scientific bridging required for non-US reference products might be more extensive than in other contexts, agency cautions; easing of the US comparator-only recommendation is one of several changes from the 2017 draft guidance that could make pursuing an interchangeability designation easier.
Woodcock Wants Rapid Regulatory Policy Development
CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.
Woodcock Wants Rapid Regulatory Policy Development
CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.